Effects of currently prescribed LDL-C-lowering drugs on PCSK9 and implications for the next generation of LDL-C-lowering agents

@inproceedings{Konrad2011EffectsOC,
  title={Effects of currently prescribed LDL-C-lowering drugs on PCSK9 and implications for the next generation of LDL-C-lowering agents},
  author={Robert J. Konrad and Jason S. Troutt and Guoqing Cao},
  booktitle={Lipids in Health and Disease},
  year={2011}
}
During the past decade, proprotein convertase subtilisin kexin type 9 (PCSK9) has been identified as a key regulator of serum LDL-cholesterol (LDL-C) levels. PCSK9 is secreted by the liver into the plasma and binds the hepatic LDL receptor, causing its subsequent degradation. In humans, gain-of-function mutations in PCSK9 cause a form of familial hypercholesterolemia that manifests with dramatically increased serum levels of LDL-C, while loss-of-function mutations in PCSK9 are associated with… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 34 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 70 references

Fibrates: therapeutic review

  • MJ Chapman
  • Br J Diabetes Vasc Dis
  • 2006
Highly Influential
4 Excerpts

MP: Niemann-Pick C1 like 1 protein is critical for intestinal cholesterol absorption

  • SW Altmann, HR JrDavis, +10 authors Graziano
  • 2004
Highly Influential
5 Excerpts

Similar Papers

Loading similar papers…